Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices reported a 50% increase in Q1 2022 revenue, reaching $8.3 million compared to the prior year. This growth was driven by a 68% rise in desktop revenue and an expanded installed base of 2,018 devices, with 83 new placements in the quarter. However, net loss widened to $9.4 million from $6.1 million a year ago, with a net loss per share of $0.30. Operating expenses increased to $13.7 million due to headcount and marketing costs. The company anticipates full-year 2022 revenue between $52 million and $55 million, indicating growth of 23% to 30% over 2021.
908 Devices (NASDAQ: MASS) announced significant updates to its MX908 handheld mass spec device, enhancing capabilities for field safety and workflows for first responders. Key improvements include enhanced Bluetooth features for iOS devices and an expanded library of drug targets, now covering fentanyl analogs and synthetic opioids. These upgrades aim to improve rapid chemical detection amidst the ongoing opioid crisis, which has seen a dramatic rise in fentanyl-related incidents.
908 Devices (Nasdaq: MASS) has partnered with the Advanced Mammalian Biomanufacturing Innovation Center to enhance biotherapeutics development. The collaboration utilizes the REBEL™ analyzer to improve monitoring and control methods across 28 active projects at five institutions, including Johns Hopkins University. The REBEL device enables real-time analysis of over 30 media nutrients, aiding projects focused on optimizing mammalian cell culture and developing new media for gene therapy. This partnership aims to lower costs and enhance efficiency in biomanufacturing.
908 Devices (NASDAQ: MASS) is collaborating with CPI to enhance mammalian cell culture techniques aimed at improving growth and protein quality. Utilizing their REBEL™ device, they analyze cell culture media to control critical process parameters. This initiative supports the biopharmaceutical industry's need for predictive modeling and real-time process control in light of advancing therapies. The REBEL allows for rapid analysis, providing insights into amino acid depletion and other metabolic factors, ultimately enhancing bioprocessing workflows.
908 Devices (NASDAQ: MASS) will release its first quarter 2022 financial results on May 10, 2022, before the market opens. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, accessible via the company's website. Known for its handheld and desktop mass spectrometry devices, 908 Devices addresses essential applications in life sciences and related fields, emphasizing quick and actionable insights.
908 Devices Inc. (MASS) reported a significant 57% year-over-year revenue increase for 2021, totaling $42.2 million. The fourth quarter revenue surged 177% to $15.8 million, driven largely by handheld device sales. Gross profit for Q4 was $9.1 million, reflecting a margin of 58%. Operating expenses rose to $12.7 million due to increased headcount and marketing efforts. The net loss decreased from $10.2 million in Q4 2020 to $3.5 million in Q4 2021. For 2022, the company projects revenue growth of 23% to 30%, aiming for $52 million to $55 million.
908 Devices (Nasdaq: MASS) has appointed Tony J. Hunt, President and CEO of Repligen Corporation (Nasdaq: RGEN), to its Board of Directors. Mr. Hunt brings over 20 years of experience in life sciences and bioprocessing. His previous roles include Chief Operating Officer at Repligen and President of Bioproduction at Life Technologies. The appointment aims to enhance 908 Devices' strategic insights and support its goal of developing a comprehensive bioanalytics platform. The company specializes in handheld mass spectrometry devices for critical applications in various markets.
908 Devices (Nasdaq: MASS) will report its fourth quarter and full year 2021 financial results on March 7, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The event will be accessible via the company’s website, with an archive available within 24 hours.
908 Devices specializes in handheld and desktop mass spectrometry devices, designed for immediate chemical and biomolecular analysis in critical applications like life sciences and forensics.
908 Devices Inc. (Nasdaq: MASS), a leader in handheld and desktop mass spectrometry, will participate in two upcoming virtual investor conferences. The first is the 11th Annual SVB Leerink Global Healthcare Conference, scheduled for February 17 at 5:40 a.m. PT. The second is the Cowen 42nd Annual Health Care Conference on March 8 at 8:10 a.m. PT. Investors can access live and archived webcasts via the company's website. 908 Devices aims to revolutionize laboratory mass spectrometry for critical applications in life sciences, bioprocessing, and more.
908 Devices Inc. (NASDAQ: MASS) reported a strong financial performance for 2021, with an estimated revenue of at least $41.5 million, a 54% increase from $26.9 million in 2020. The fourth quarter showed remarkable growth, anticipating revenues of at least $15.1 million, up 165% from $5.7 million in Q4 2020. CEO Kevin J. Knopp noted continued execution of their commercial strategy and plans for future growth in key accounts and product development, as they prepare to release full audited financial results in early March.